文献速递耳科与耳神经头颈外科

头颈癌放化疗听力损失预测模型的验证

Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2021-01-01

该队列研究纳入105例新诊断头颈癌患者(208耳),验证既往建立的放疗±顺铂化疗后听力损失预测模型。校准曲线显示预测与观察的纯音平均听阈无显著差异;模型预测治疗后纯音平均听阈>35 dB的敏感度73%、特异度67%,AUC为0.71,区分度良好;临床医生访谈提示列线图需谨慎整合入患者咨询。

要点

  • 模型预测治疗后纯音平均听阈>35 dB的敏感度73%、特异度67%,AUC 0.71。
  • 校准曲线显示预测与观察的纯音平均听阈无显著差异。
  • 列线图需谨慎整合入患者咨询以阐明治疗风险与获益。

核心结论

  • 该队列研究证实该模型能在特定头颈癌患者群体中预测治疗后听力结局。
  • 该模型有望用于治疗前咨询和治疗后听力评估。

研究设计与样本

  • 队列研究,纳入105例新诊断头颈癌患者(208耳),均接受放疗,其中50例(48%)接受顺铂化疗,67例(64%)接受手术切除。
  • 患者于2018年7月1日至2019年12月31日在Siteman癌症中心治疗,并访谈6名临床医生评估实施策略。

主要发现

  • 患者平均(SD)年龄61(11)岁,男性82例(78%)。
  • 接受顺铂化疗者平均(SD)顺铂总剂量为238(83)mg/m2,耳蜗平均(SD)放疗剂量为13(12)Gy。
  • 校准曲线显示预测与观察的治疗后纯音平均听阈无显著差异。
  • 模型预测治疗后纯音平均听阈>35 dB的敏感度73%、特异度67%,AUC为0.71。

关键数值与推荐

  • 听力结局以1、2、4 kHz纯音平均听阈定义。
  • 模型预测治疗后纯音平均听阈>35 dB(考虑助听器的常用阈值)的敏感度73%、特异度67%,AUC 0.71。

临床怎么用

  • 该模型可用于头颈癌患者放化疗前咨询,帮助患者了解听力损失风险。
  • 列线图需谨慎整合入患者咨询,以阐明治疗风险与获益。
  • 模型可辅助治疗后听力评估的决策。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hearing loss affects up to 88% of patients undergoing head and neck cancer treatment; however, there are few validated models to predict this outcome. A predictive posttreatment model for hearing loss will allow clinicians and patients to make well-informed decisions about treatment with cisplatin-based chemotherapies and radiotherapy. OBJECTIVE: To validate a previously created predictive model for objective hearing outcomes and to assess barriers to using the prediction nomogram in general practice for patients newly diagnosed with head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: This cohort study includes an evaluation of 105 patients (208 ears) and interviews with 6 clinicians. The patients were treated at a high-volume tertiary care hospital. Patient participants were newly diagnosed with head and neck cancer and treated at Siteman Cancer Center from July 1, 2018, to December 31, 2019, with radiotherapy both with and without cisplatin-based chemotherapy. Additionally, the clinicians involved in the care of patients with head and neck cancer were interviewed to assess implementation strategies. EXPOSURES: Radiotherapy with and without cisplatin-based chemotherapy. MAIN OUTCOMES AND MEASURES: Hearing defined by the audiometric pure-tone average of 1, 2, and 4 kHz. RESULTS: A total of 105 patients (208 ears; mean [SD] age, 61 [11] years; 82 men [78%]) were compared with the development cohort to assess the similarities and differences in case mix. All patients underwent radiation therapy, 50 (48%) received cisplatin-based chemotherapy, and 67 (64%) had a surgical resection. The mean (SD) cochlear dose of radiation was 13 (12) Gy, and the mean (SD) total cisplatin dose was 238 (83) mg/m2 for those undergoing cisplatin therapy. A calibration curve demonstrated that predicted and observed posttreatment pure-tone average were not significantly different. The model predicted a posttreatment pure-tone average greater than 35 dB (a common threshold for hearing aid consideration) with a sensitivity of 73% and specificity of 67% with an area under the curve of 0.71, showing good discrimination. Clinician interviews suggest the nomogram requires careful integration into patient counseling to clarify risks and benefits for treatment. CONCLUSIONS AND RELEVANCE: The findings of this cohort study confirm this model's ability to predict posttreatment hearing outcomes in a unique population of patients. This model has the potential to inform pretreatment counseling and posttreatment hearing evaluations for this patient population.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Deutsch BC, Collopy C, Kallogjeri D, et al. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33300954. doi:10.1001/jamaoto.2020.4620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。